Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Camonsertib by Repare Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Camonsertib by Repare Therapeutics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...
Camonsertib by Repare Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Camonsertib by Repare Therapeutics for Solid Tumor: Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Camonsertib by Repare Therapeutics for Pancreatic Cancer: Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Camonsertib by Repare Therapeutics for Ovarian Cancer: Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Camonsertib by Repare Therapeutics for Breast Cancer: Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
Camonsertib by Repare Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
Camonsertib by Repare Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...